Tharimmune abstracts accepted for presentation at upcoming ddw and easl conferences

Bridgewater, nj / access newswire / may 1, 2025 / tharimmune, inc., (nasdaq:thar) ("tharimmune" or the "company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology announced abstracts featuring clinical data on its lead drug candidate, th104, have been accepted for presentation at the digestive disease week (ddw) annual meeting and at the european association for the study of the liver (easl) international liver congress. both conferences will take place in may 2025.
THAR Ratings Summary
THAR Quant Ranking